84 PART TWO | CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING 32. https://www.accessdata. fda.gov/drugsatfda_docs/ label/2010/021793s008lbl.pdf. (22 March 2019 date last accessed) 33. Jordan K, Blättermann L, Hinke A et al. Is the addition of a neurokinin-1 receptor antagonist beneficial in moderately emetogenic chemotherapy?-a systematic review and meta-analysis. Support Care Cancer 2018;26:21-32. 34. Navari RM, Qin R, Ruddy KJ et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med 2016;375:134-42. 35. Mizukami N, Yamauchi M, Koike K et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebocontrolled study. J Pain Symptom Manage. 2014;47:542-50. 36. SY, Han HS, Bae WK et al. A randomized, double-blind, placebo-controlled study of the safety and efficacy of olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: results of the Korean South West Oncology Group (KSWOG) Study. Cancer Res Treat 2019;51:90-7. 37. Molassiotis A, Aapro M, Dicato M et al. Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study. J Pain Symptom Manage 2014;47:839-48. 38. Pirri C, Katris P, Trotter J et al. Risk factors at pretreatment predicting treatmentinduced nausea and vomiting in Australian cancer patients: a prospective, longitudinal, observational study. Support Care Cancer 2011;19:1549-63.
RkJQdWJsaXNoZXIy MjY0ODMw